Lucid Diagnostics Inc
LUCD1.030USD
+0.030+3.00%
시장 운영 시간 （ET）시세는 15분 지연됩니다
86.91M시가총액
손실P/E TTM
자세한 내용은 Lucid Diagnostics Inc 회사
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.
회사 정보
종목 코드 LUCD
회사 이름Lucid Diagnostics Inc
상장일Oct 14, 2021
CEODr. Lishan Aklog, M.D.
직원 수72
유형Ordinary Share
회계 연도 종료Oct 14
주소360 Madison Avenue
도시NEW YORK
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호10017
전화12129494319
웹사이트https://www.luciddx.com/
종목 코드 LUCD
상장일Oct 14, 2021
CEODr. Lishan Aklog, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.47M
-4.86%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.32M
-5.38%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
462.80K
+310.28%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
197.46K
-53.33%
Dr. Jacque J. Sokolov, M.D.
Dr. Jacque J. Sokolov, M.D.
Independent Director
Independent Director
197.46K
-8.99%
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.47M
-4.86%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.32M
-5.38%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
462.80K
+310.28%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
197.46K
-53.33%
수익 분석
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
데이터 없음
지역별USD
이름
수익
비율
United States
828.00K
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 24
마지막 업데이트: Sat, May 24
주주
주주 유형
주주
주주
비율
PAVmed Inc
28.93%
Masters Capital Management, L.L.C.
2.52%
Alyeska Investment Group, L.P.
1.74%
Aklog (Lishan)
1.36%
McGrath (Dennis M)
1.22%
Other
64.23%
주주
주주
비율
PAVmed Inc
28.93%
Masters Capital Management, L.L.C.
2.52%
Alyeska Investment Group, L.P.
1.74%
Aklog (Lishan)
1.36%
McGrath (Dennis M)
1.22%
Other
64.23%
주주 유형
주주
비율
Corporation
28.93%
Hedge Fund
7.03%
Individual Investor
5.61%
Investment Advisor
2.15%
Investment Advisor/Hedge Fund
0.79%
Research Firm
0.18%
Other
55.31%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
94
48.34M
44.68%
+6.89M
2025Q1
87
48.55M
48.13%
+9.11M
2024Q4
72
40.61M
68.54%
+2.85M
2024Q3
67
37.54M
71.75%
+1.52M
2024Q2
80
37.13M
71.19%
+1.04M
2024Q1
96
36.05M
80.31%
-3.56M
2023Q4
96
34.89M
79.71%
-1.40M
2023Q3
97
35.04M
80.14%
-1.22M
2023Q2
93
35.02M
80.10%
-1.13M
2023Q1
94
35.12M
89.38%
+2.48M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
PAVmed Inc
31.30M
28.93%
--
--
Dec 06, 2024
Masters Capital Management, L.L.C.
2.73M
2.52%
+2.73M
--
Mar 31, 2025
Alyeska Investment Group, L.P.
1.89M
1.74%
+1.89M
--
Mar 31, 2025
Aklog (Lishan)
1.47M
1.36%
-75.00K
-4.86%
Apr 22, 2025
McGrath (Dennis M)
1.32M
1.22%
-75.00K
-5.38%
Apr 22, 2025
Ayrton Capital LLC
1.20M
1.11%
+1.18M
+7216.46%
Dec 31, 2024
The Vanguard Group, Inc.
888.87K
0.82%
+327.96K
+58.47%
Mar 31, 2025
O'Neil (Shaun)
826.76K
0.76%
-50.00K
-5.70%
Apr 22, 2025
Gordon (Michael Adam)
700.00K
0.65%
-183.33K
-20.75%
Apr 22, 2025
Matheis (Dennis)
462.80K
0.43%
+350.00K
+310.28%
May 22, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.02%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
비율0.02%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
ProShares Hedge Replication ETF
비율0%
iShares Russell 2000 ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
iShares Russell 2000 Value ETF
비율0%
Global X Russell 2000 ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Proshares Ultra Russell 2000
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
